Congratulations to 2022 Postdoctoral Fellow Giovanni Bellomo for his role in the development and clinical validation of two new assays for DOPA decarboxylase, a potentially promising biomarker for PD/Lewy body disorders.
Check out the paper: www.nature.com/articles/s41...
www.nature.com
Using two newly developed immunoassays tested in three clinical cohorts, this study highlights CSF DOPA decarboxylase as a promising biomarker for differentiating dementia with Lewy bodies and Parkins...
